Jade Biosciences Inc. is focused on developing therapies to address critical unmet needs in autoimmune diseases. The company pipeline includes antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade Biosciences Inc., formerly known as Aerovate Therapeutics Inc., is based in WALTHAM, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-127.41M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.04 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -49.11% |
| Return on Assets (Trailing 12 Months) | -45.62% |
| Current Ratio (Most Recent Fiscal Quarter) | 14.93 |
| Quick Ratio (Most Recent Fiscal Quarter) | 14.93 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.92 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.76 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.19 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.92 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 63.60M |
| Free Float | 48.93M |
| Market Capitalization | $1.34B |
| Average Volume (Last 20 Days) | 0.73M |
| Beta (Past 60 Months) | 1.45 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 23.06% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |